Ruidafu Medical Completes Series B Financing Led by CICC Capital to Accelerate Innovation and Globalization in Domestic Assisted Reproductive Technology

VCBeat has learned that in April 2025, Jiangsu Ruifuda Medical Instrument Co., Ltd. (Ruifuda Medical) successfully completed its Series B financing round, which was led byFunds Managed by CICC CapitalLead investor,Lianyungang Economic and Technological Development Zone Industrial FundCo-investment. The funds raised will be primarily invested in R&D for core products, domestic and international market expansion, production capacity upgrades, and team building, injecting strong momentum into the company's development.

Upholding the development philosophy of “Ruitong Heritage, Furen Craftsmanship, Empowering Others to Empower Oneself,” Ruifuda Medical has, since its establishment in Lianyungang, Jiangsu in 2018, always taken it as its mission to help families struggling with infertility realize their dreams of parenthood, and is committed to the domestic research and development of medical reagents and consumables in the field of assisted reproduction.

The company’s founding team boasts over 20 years of in-depth industry experience, having been fully involved in the entire process from laboratory products to standardized industrialization. It has established a rare, integrated system encompassing R&D, production, and operations, and created an efficient collaborative innovation platform linking industry, academia, research, and clinical practice. Leveraging its Class 100 cleanroom facilities, advanced R&D center, and testing laboratories, along with close collaborations with top-tier domestic and international reproductive medicine centers, the company has filed six invention patents and built an independent intellectual property portfolio. In March 2025, it successfully obtained certification as a National High-Tech Enterprise, an authoritative recognition of its R&D capabilities and technological achievement commercialization.

In terms of technological products, Ruifuda Medical has recently achieved significant breakthroughs—

Closed Cryo-Loading Rod (Launched in March 2025):By leveraging world-first patented technology and a unique liquid refrigerant design, it has successfully addressed the critical industry challenge in vitrification cryopreservation of balancing rapid cooling with closed-system contamination prevention. This provides an optimized solution for enhancing the safety of assisted reproductive technologies, embodying its commitment to “Benevolent Craftsmanship.”

Oocyte Optimization Solution:As the world’s first professional and highly efficient oocyte cytoplasmic maturation optimization medium, this product features antioxidant properties that significantly improve oocyte quality, increase the rate of high-quality embryos, and enhance blastocyst formation rates. It provides a breakthrough, personalized therapeutic approach for challenging cases such as impaired oocyte maturation competence, diminished ovarian reserve, and recurrent poor embryo quality, thereby putting the philosophy of “helping others to help oneself” into practice.

International Certification:On April 11, 2025, the company’s independently developed vitrification cryopreservation and thawing solution kit officially received registration approval from the U.S. Food and Drug Administration (FDA). This milestone signifies that its product quality control system, safety, and efficacy have reached an internationally leading level, laying a solid foundation for entry into high-end overseas markets and demonstrating the technological accumulation of its “Ruitong Heritage” platform.

Based on this, Ruifuda Medical is actively advancing its strategic layout: while accelerating product commercialization and capacity expansion in China, it is leveraging FDA certification as a starting point to vigorously expand into international markets. The company aims to enable more patients with infertility and individuals seeking fertility preservation worldwide to benefit from high-quality Chinese medical solutions, thereby promoting Chinese reproductive technology brands on the global stage and realizing its vision of “empowering others.”

CICC CapitalIn evaluating this investment, it was stated: “Ruifuda Medical has demonstrated strong R&D capabilities and efficient industrialization in the niche field of assisted reproduction, standing out as a leader among domestically produced medical devices. We look forward to supporting the company through this round of investment to build more robust technical barriers and broader market prospects, driven by the dual engines of domestic substitution and international expansion.”

Head of Investment Promotion, Lianyungang China Pharmaceutical PortIt stated: “As a representative enterprise of the medical device sector in Lianyungang’s China Pharmaceutical Port, Ruifuda possesses strong development potential and momentum. We remain unwavering in our support for the company’s growth, fully leveraging the guiding role of industrial investment funds to aggregate more resources and help Ruifuda maintain a leading position in the field of assisted reproduction.”

Ruifuda MedicalEmphasis: “This Series B financing round represents a key milestone in the company’s development and marks a significant step toward higher standards for domestically produced assisted reproductive technology devices. Leveraging this opportunity, the company will continue to drive technological innovation, strengthen quality control, enhance service capabilities, and accelerate the widespread global adoption of its core products.”

Located in Lianyungang, Jiangsu, it is a leading enterprise dedicated to the domestic R&D of reagents and consumables for assisted reproduction. Guided by the core philosophy of “Inheriting Ruitong’s Legacy, Upholding Benevolent Craftsmanship, and Achieving Mutual Success,” it is committed to contributing to the health of future generations.

As the private equity investment platform under CICC, it has long been deeply engaged in national strategic emerging industries, with profound layout and unique investment insight especially in the fields of biomedicine and medical devices. Its lead investment fully demonstrates high recognition of Ruifuda Medical's technical strength, development philosophy, and market prospects, and will provide strong resource support for the company's subsequent development.